Skip to main content

Sources last read

Oncology · approved care and active research

Peptides and cancer: four different things

Peptides already have real roles in cancer care. The roles are not alike: one approved drug carries radiation. Another copies a hormone signal. A custom vaccine is still in a trial. An LL-37 trial treated three people.

Source for this answer

Source: Two FDA labels, one NCI guide and two trial records, read 2026-08-16

Source: Two FDA labels, one NCI guide and two trial records, read 2026-08-16

What matters first

Approved roles
Radiation delivery and hormone signaling
Custom peptide vaccine
Still in a clinical trial
LL-37 study
Four enrolled; three treated
Rule
Judge the exact treatment and evidence stage

“Peptide” tells you what a molecule is made from. It does not tell you what the treatment does, which tumor it targets or whether it has passed a clinical trial. Start with the role and the evidence stage.

Treatment and research

Same word, four different jobs

Some peptide drugs are approved for specific cancers. Others are still being tested. A result for one drug does not show that another peptide will work.

01FDA-approved for a named cancer

A peptide carries radiation to a tumor receptor

Lutathera (lutetium Lu 177 dotatate)

What studies show
The label calls it a radioactive somatostatin analog. It targets gastroenteropancreatic neuroendocrine tumors that carry the right receptor.
What this does not show
This is a hospital radiopharmaceutical for receptor-positive tumors, not evidence that an unrelated wellness peptide treats cancer.
02FDA-approved for a named cancer

A peptide analog acts as the drug itself

Somatuline Depot (lanreotide)

What studies show
The label covers a defined group of gastroenteropancreatic neuroendocrine tumors. They may be advanced, metastatic or unable to be removed by surgery.
What this does not show
An approval for a defined neuroendocrine-tumor population does not make peptide products a general cancer-treatment class.
03Recruiting phase 1 · no results

Peptides teach the immune system what to recognize

Personalized synthetic long-peptide vaccine

What studies show
NCT06529822 plans to enroll 64 people. It asks about safety. It also asks if each custom vaccine can be made and delivered on time.
What this does not show
A recruiting feasibility study has no treatment result. NCI describes antigen-based cancer vaccines as experimental.
04Completed phase 1/2 · 3 treated

A familiar research peptide is injected into a tumor

LL-37 in melanoma

What studies show
In NCT02225366, four people enrolled, but three received treatment. The main outcome was the highest tolerated dose of LL-37 injected into melanoma tumors.
What this does not show
This small dose-finding study does not establish that LL-37 treats melanoma. It did not test routine injections elsewhere in the body.
Open the LL-37 record

Approved cancer medicines

This is not a future-only field

Lutathera and lanreotide show two ways these drugs already appear in cancer care. One carries radiation to a tumor with the right receptor. The other copies a hormone signal.

The approval belongs to the exact drug, tumor type, route and evidence package on the label. It does not transfer to another peptide because both are made from amino acids.

How to read the next headline

Five questions before “peptide” becomes “cancer treatment”

  1. What is the peptide doing? It may be the drug, carry radiation or present a tumor target to immune cells.
  2. Which tumor and marker? A receptor-positive neuroendocrine tumor is not “cancer” in general.
  3. What stage is the evidence? FDA approval, recruiting phase 1 and a small completed dose-finding study are different answers.
  4. What was the main outcome? Safety or dose finding cannot be restated as tumor control.
  5. Does the claim match the route? An injection into a tumor does not establish a routine injection under the skin.

Keep reading

5primary sources, each with the day we read it — open the documents used on this page